Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia
Guillermo Montalban‐Bravo(The University of Texas MD Anderson Cancer Center), Simona Colla(The University of Texas MD Anderson Cancer Center)
Cited by 14
Related Papers
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
|Journal of Clinical Oncology|2021|333
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
|The Lancet Haematology|2020|330
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
|Nature Medicine|2022|81
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation
|Nature Genetics|2025|10